Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 3359-3369

  Theiss, Hans D ^a   Gross, Lisa ^a   Vallaster, Markus ^a   David, Robert ^a   Brunner, Stefan ^a   Brenner, Christoph ^a   Nathan, Petra ^a   Assmann, Gerald ^b   Mueller Hoecker, Josef ^b   Vogeser, Michael ^b   Steinbeck, Gerhard ^a   Franz, Wolfgang M ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute myocardial infarction; DPP IV; G CSF; Sitagliptin; Stem cell homing

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1; VILDAGLIPTIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HOMING; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CORONARY ARTERY LIGATION; FLOW CYTOMETRY; HEART CATHETERIZATION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; IMMUNOHISTOLOGY; KAPLAN MEIER METHOD; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MASS SPECTROMETRY; MONOTHERAPY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ACUTE MYOCARDIAL INFARCTION; DPP-IV; G-CSF; SITAGLIPTIN; STEM CELL HOMING;

ADAMANTANE; ANIMALS; CELL SURVIVAL; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEART; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; NITRILES; PYRAZINES; PYRROLIDINES; TRIAZOLES;

EID: 84886284739     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.04.121     Document Type: Article

References (27)

1. K. Dickstein, A. Cohen-Solal, and G. Filippatos ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 2008 933 989
2. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053
3. + cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines J Clin Invest 116 2006 1865 1877
4. A.A. Kocher, M.D. Schuster, and M.J. Szabolcs Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function Nat Med 7 2001 430 436
5. M.M. Zaruba, B.C. Huber, and S. Brunner Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival Cardiovasc Res 77 2008 722 731
6. M.M. Zaruba, H.D. Theiss, and M. Vallaster Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction Cell Stem Cell 4 2009 313 323
7. D.J. Ceradini, A.R. Kulkarni, and M.J. Callaghan Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat Med 10 2004 858 864
8. A.T. Askari, S. Unzek, and Z.B. Popovic Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy Lancet 362 2003 697 703
9. M.P. Crump, J.H. Gong, and P. Loetscher Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1 EMBO J 16 1997 6996 7007
10. W.M. Franz, M. Zaruba, H. Theiss, and R. David Stem-cell homing and tissue regeneration in ischaemic cardiomyopathy Lancet 362 2003 675 676
11. K.W. Christopherson II, G. Hangoc, C.R. Mantel, and H.E. Broxmeyer Modulation of hematopoietic stem cell homing and engraftment by CD26 Science 305 2004 1000 1003
12. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
13. G.A. Herman, C. Stevens, and K. Van Dyck Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 78 2005 675 688
14. H.D. Theiss, C. Brenner, and M.G. Engelmann Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-Trial) - rationale, design and first interim analysis Int J Cardiol 145 2010 282 284
15. D. Marguet, L. Baggio, and T. Kobayashi Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 Proc Natl Acad Sci U S A 97 2000 6874 6879
16. E. Deindl, M.M. Zaruba, and S. Brunner G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis FASEB J 20 2006 956 958
17. S. Scharpe, I. De Meester, and G. Vanhoof Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine Clin Chem 34 1988 2299 2301
18. Y.Y. Zhou, S.Q. Wang, and W.Z. Zhu Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology Am J Physiol Heart Circ Physiol 279 2000 H429 H436
19. P.A. Read, F.Z. Khan, P.M. Heck, S.P. Hoole, and D.P. Dutka DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease Circ Cardiovasc Imaging 3 2010 195 201
20. G.P. Fadini, E. Boscaro, and M. Albiero The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha Diabetes Care 33 2010 1607 1609
21. M. Sauve, K. Ban, and M.A. Momen Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
22. S. Basu, A. Dunn, and A. Ward G-CSF: function and modes of action (Review) Int J Mol Med 10 2002 3 10
23. L.A. Nikolaidis, S. Mankad, and G.G. Sokos Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
24. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
25. Y. Ye, K.T. Keyes, C. Zhang, J.R. Perez-Polo, Y. Lin, and Y. Birnbaum The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA Am J Physiol Heart Circ Physiol 298 2010 H1454 H1465
26. H.D. Theiss, M. Vallaster, and C. Rischpler Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis Stem Cell Res 2011
27. H.D. Theiss, C. Brenner, and M.G. Engelmann Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-Trial) - rationale, design and first interim analysis Int J Cardiol 145 2010 282 284